Abbott Laboratories (NYSE:ABT) stock rose 1.30% (As on July 19, 11:11:04 AM UTC-4, Source: Google Finance) after the company reported second-quarter earnings that edged past Wall Street expectations and raised its full-year adjusted earnings guidance, signaling confidence in its diversified healthcare portfolio. The company’s second-quarter performance was bolstered by a 9.3% organic sales growth in its underlying base business, led by a notable double-digit increase in the Medical Devices segment. This growth comes despite the continued phase-out of COVID-19 testing-related sales, which have declined as the pandemic transitions to an endemic phase. Worldwide Nutrition sales increased 3.5 percent on a reported basis and 7.5 percent on an organic basis in the second quarter.

ABT in the second quarter of FY 24 has reported the adjusted earnings per share of $1.14, beating the analysts’ estimates for the adjusted earnings per share of $1.11. The company had reported the adjusted revenue growth of 4 percent to $10.38 billion in the second quarter of FY 24, beating the analysts’ estimates for revenue of $10.37 billion.

Meanwhile, in April, Abbott announced U.S. Food and Drug Administration (FDA) approval of the Esprit below-the-knee (BTK) system, a breakthrough innovation for people living with peripheral artery disease. This system is designed to keep arteries open and deliver a drug to support vessel healing prior to completely dissolving. In June, Abbott announced U.S. FDA clearance for two new over-the-counter continuous glucose monitoring systems — Lingo and Libre Rio, which are based on Abbott’s world-leading FreeStyle Libre continuous glucose monitoring technology. In June, Abbott obtained CE Mark for its AVEIR® dual chamber (DR) leadless pacemaker system, the world’s first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms. During the first half of 2024, Abbott announced 10 new growth opportunities coming from the company’s highly productive R&D pipeline. These include a combination of new product approvals and new treatment indications.

For the third quarter of 2024, Abbott anticipates adjusted diluted EPS to be between $1.18 and $1.22, excluding specified items, which is also in line with analysts’ expectations.

The healthcare giant also lifted its full-year 2024 EPS forecast to a range of $4.61 to $4.71, from its previous projection, which now stands slightly above the midpoint compared to the analyst consensus of $4.63.  Abbott narrowed its full-year 2024 organic sales growth guidance range, excluding COVID-19 testing-related sales, to 9.5% to 10.0%.